The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
Boosting the Public Sector Cybersecurity Workforce
ISC2's Tara Wisniewski spoke about skills-based hiring in cybersecurity and how agencies can hire cyber pros easier.
11m listen -
NIST Center Helps Translate Cyber Standards into Practice
Interagency agreements and the collaboration model at the National Cybersecurity Center of Excellence advance cybersecurity.
15m listen -
DISA Using AI to Secure Multi-Cloud Environments
The Defense Information Systems Agency is harnessing artificial intelligence to secure multi-cloud environments.
13m listen -
How an NCI Data Registry is Helping Diagnose, Treat Rare Pediatric Cancers
The Rare Cancer Initiative is enabling the research community to access more clinical data to improve health outcomes for children diagnosed with rare cancers.
20m listen
